Matthew R. Smith, MD, PhD

Matthew R. Smith, MD, PhD, is a professor of medicine at Harvard Medical School and director of the Genitourinary Malignancies Program at Massachusetts General Hospital Cancer Center. He received his MD and PhD degrees from Duke University School of Medicine, and he completed his internal medicine training at Brigham and Women's Hospital, a medical oncology fellowship at Dana-Farber Cancer Institute, and a postdoctoral fellowship at Massachusetts Institute of Technology.

Dr Smith is a clinical investigator and innovator with expertise in new drug development in prostate cancer. He has contributed to the conception, design, and leadership of multiple phase 3 studies in prostate cancer, including pivotal studies that supported new US Food and Drug Administration (FDA) drug approvals of denosumab, apalutamide, and darolutamide. He has authored more than 250 peer-reviewed articles on prostate cancer, including manuscripts published in The New England Journal of Medicine, The Lancet, the Journal of Clinical Oncology, Cancer, The Journal of Clinical Endocrinology and Metabolism, and Clinical Cancer Research.